S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and GOP rush to complete debt ceiling deal, shore up support to prevent default
15 A.I. Trading Opportunities a Day (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
15 A.I. Trading Opportunities a Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and GOP rush to complete debt ceiling deal, shore up support to prevent default
15 A.I. Trading Opportunities a Day (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
15 A.I. Trading Opportunities a Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and GOP rush to complete debt ceiling deal, shore up support to prevent default
15 A.I. Trading Opportunities a Day (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
15 A.I. Trading Opportunities a Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and GOP rush to complete debt ceiling deal, shore up support to prevent default
15 A.I. Trading Opportunities a Day (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
15 A.I. Trading Opportunities a Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
NASDAQ:ENTX

Entera Bio (ENTX) Stock Forecast, Price & News

$0.79
+0.02 (+2.61%)
(As of 05/26/2023 ET)
Compare
Today's Range
$0.74
$0.85
50-Day Range
$0.68
$1.35
52-Week Range
$0.47
$2.38
Volume
33,338 shs
Average Volume
44,342 shs
Market Capitalization
$22.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50

Entera Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
854.3% Upside
$7.50 Price Target
Short Interest
Healthy
0.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.44mentions of Entera Bio in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$30,300 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.31) to ($0.76) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

320th out of 1,012 stocks

Biological Products, Except Diagnostic Industry

45th out of 169 stocks


ENTX stock logo

About Entera Bio (NASDAQ:ENTX) Stock

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.

Receive ENTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter.

ENTX Stock News Headlines

3 Free Stock Picks per Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Entera Bio: Q1 Earnings Insights
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
Entera Bio (NASDAQ:ENTX) Rating Reiterated by HC Wainwright
H.C. Wainwright Sticks to Their Buy Rating for Entera Bio (ENTX)
Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?
See More Headlines
Receive ENTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter.

ENTX Company Calendar

Last Earnings
11/11/2021
Today
5/28/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ENTX
Fax
N/A
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.50
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+854.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-13,070,000.00
Net Margins
-9,754.48%
Pretax Margin
-17,171.21%

Debt

Sales & Book Value

Annual Sales
$130,000.00
Book Value
$0.35 per share

Miscellaneous

Free Float
27,321,000
Market Cap
$22.63 million
Optionable
Not Optionable
Beta
1.82

Key Executives

  • Miranda J. Toledano
    Chief Executive Officer & Director
  • Hillel Galitzer
    Chief Operating Officer
  • Dana Yaacov Garbeli
    Chief Financial Officer
  • Gregory Burshtein
    Vice President-Research & Development
  • Anke Hoppe
    Vice President-Clinical Operations













ENTX Stock - Frequently Asked Questions

Should I buy or sell Entera Bio stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ENTX shares.
View ENTX analyst ratings
or view top-rated stocks.

What is Entera Bio's stock price forecast for 2023?

2 equities research analysts have issued 12-month price targets for Entera Bio's shares. Their ENTX share price forecasts range from $5.00 to $10.00. On average, they expect the company's share price to reach $7.50 in the next year. This suggests a possible upside of 854.3% from the stock's current price.
View analysts price targets for ENTX
or view top-rated stocks among Wall Street analysts.

How have ENTX shares performed in 2023?

Entera Bio's stock was trading at $0.73 at the beginning of the year. Since then, ENTX stock has increased by 7.7% and is now trading at $0.7859.
View the best growth stocks for 2023 here
.

Are investors shorting Entera Bio?

Entera Bio saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 37,600 shares, a decline of 23.7% from the April 30th total of 49,300 shares. Based on an average daily volume of 230,300 shares, the short-interest ratio is presently 0.2 days. Currently, 0.2% of the shares of the stock are sold short.
View Entera Bio's Short Interest
.

When is Entera Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ENTX earnings forecast
.

How were Entera Bio's earnings last quarter?

Entera Bio Ltd. (NASDAQ:ENTX) issued its quarterly earnings data on Thursday, November, 11th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.03. The company earned $0.14 million during the quarter. Entera Bio had a negative net margin of 9,754.48% and a negative trailing twelve-month return on equity of 85.95%.

What other stocks do shareholders of Entera Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include Fulcrum Therapeutics (FULC), Cara Therapeutics (CARA), Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Vaxart (VXRT), AbbVie (ABBV), Acasti Pharma (ACST) and Allena Pharmaceuticals (ALNA).

When did Entera Bio IPO?

(ENTX) raised $11 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 1,400,000 shares at $8.00 per share. Maxim Group served as the underwriter for the IPO and Joseph Gunnar was co-manager.

What is Entera Bio's stock symbol?

Entera Bio trades on the NASDAQ under the ticker symbol "ENTX."

How do I buy shares of Entera Bio?

Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Entera Bio's stock price today?

One share of ENTX stock can currently be purchased for approximately $0.79.

How much money does Entera Bio make?

Entera Bio (NASDAQ:ENTX) has a market capitalization of $22.63 million and generates $130,000.00 in revenue each year. The company earns $-13,070,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

How can I contact Entera Bio?

Entera Bio's mailing address is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. The official website for the company is www.enterabio.com. The company can be reached via phone at (722) 532-7151 or via email at investorrelations@enterabio.com.

This page (NASDAQ:ENTX) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -